Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

784
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
784
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Diphtheria01:28

Diphtheria

175
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
175

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and evaluation of a values-based anti-doping education program for university sport in Japan: the UNIVAS clean sports intervention.

Frontiers in sports and active living·2026
Same author

Investigating the electronic and magnetic properties of Na <sub><i>x</i></sub> Fe<sub>1/2</sub>Mn<sub>1/2</sub>O<sub>2</sub> cathode materials with X-ray Compton scattering.

RSC advances·2026
Same author

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same author

Polyoxometalate-modified platinum enables enhanced hydrogen evolution in buffered electrolytes.

Chemical communications (Cambridge, England)·2026
Same author

Reporting of Y Balance Test Measurement Procedures in Reliability and Validity Studies: A Scoping Review.

Sports (Basel, Switzerland)·2026
Same author

Longitudinal changes in brain volume, cognitive function, and seizure outcomes in cryptogenic new-onset refractory status epilepticus.

Journal of the neurological sciences·2026

Related Experiment Video

Updated: May 3, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.0K

[Prophylactic treatment with botulinum toxin type A].

Kosuke Suzuki1, Takahiro Iizuka, Fumihiko Sakai

  • 1Department of Neurology, School of Medicine, Kitasato University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 13, 2005
PubMed
Summary

Migraine treatment in Japan is improving. Botulinum toxin type A (BoNT-A) shows promise for prophylaxis, with ongoing studies evaluating its effectiveness and optimal use.

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • Migraine is a prevalent neurological disorder affecting 8.4% of Japan's population.
  • Current acute migraine treatments, like triptans, are effective, but prophylactic options remain limited.

Purpose:

  • To review controlled trials on Botulinum toxin type A (BoNT-A) for migraine.
  • To discuss BoNT-A's methodology, dosage, patient selection, and mechanisms in the context of Japanese migraine patients.

Summary:

  • Botulinum toxin type A (BoNT-A) has demonstrated efficacy in international randomized controlled trials for migraine prophylaxis.
  • This review synthesizes findings from recent trials, addressing key aspects for clinical application.
  • An ongoing prospective study in Japan will further investigate BoNT-A's role.

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 4, 2014

15.6K
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K

Related Experiment Videos

Last Updated: May 3, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.0K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 4, 2014

15.6K
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K

Impact:

  • This review provides crucial insights for the potential introduction and application of BoNT-A in Japan.
  • It highlights the need for further research, including prospective studies, to optimize BoNT-A therapy for Japanese migraine sufferers.